Print Page  |  Close Window

2016 Press Releases

E-mail Alerts Receive E-mail Alerts | RSS RSS Feeds
Keyword Search
 
2016 | 2015 | 2014 | 2013 | 2012
DateTitle 
01/27/16LabCorp and Cheeriodicals Spread Cheer to UNC Children’s
CHAPEL HILL & BURLINGTON, N.C.--(BUSINESS WIRE)--Jan. 27, 2016-- A team from Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH), along with Cheeriodicals, delivered cheer in the form of 160 big green boxes to patients at N.C. Children’s Hospital during a "Cheeriodicals Day" event held on Jan. 27. Cheeriodicals are "big green boxes of cheer" made up of, in this case, age-appropriate magazines and activity books, room decorations, puzzles, ... 
Printer Friendly Version
01/07/16LabCorp Announces New Board Member
Richelle Parham Named to the Board of Directors Effective February 8, 2016 BURLINGTON, N.C.--(BUSINESS WIRE)--Jan. 7, 2016-- Laboratory Corporation of America® Holdings (LabCorp®) (NYSE:LH) today announced that Richelle Parham has been appointed to its Board of Directors, effective February 8, 2016. “We are delighted that Richelle has accepted our invitation to join the LabCorp Board of Directors,” said David P. King, chairman and chie... 
Printer Friendly Version
01/06/16LabCorp is Scheduled to Present at the 34th Annual J.P. Morgan Healthcare Conference
BURLINGTON, N.C.--(BUSINESS WIRE)--Jan. 6, 2016-- Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) today announced it will participate at the 34th Annual J.P. Morgan Healthcare Conference. LabCorp’s presentation is scheduled for Wednesday, January 13, 2016 at 11:00 AM (ET). A live audio webcast of the presentation will be available via the Company website at www.labcorp.com and archived for replay. About Lab... 
Printer Friendly Version
01/04/16Proprietary LabCorp Clinical Decision Support Report Improves Adherence to Chronic Kidney Disease Treatment Guidelines
BURLINGTON, N.C.--(BUSINESS WIRE)--Jan. 4, 2016-- Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) today announced the results of a recently published clinical research study that demonstrates improved physician adherence to chronic kidney disease (CKD) treatment guidelines through the use of LabCorp’s innovative clinical decision support (CDS) report. Treatment guidelines provide evidence-based information to help physicians and ... 
Printer Friendly Version
01/04/16Conversion Right Triggered for LabCorp’s Zero Coupon Convertible Subordinated Notes Due 2021
BURLINGTON, N.C.--(BUSINESS WIRE)--Jan. 4, 2016-- Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) announced today that its Zero Coupon Convertible Subordinated Notes due 2021 (Zero Coupon Notes) may be converted as set forth below. The Zero Coupon Notes are convertible into cash and Common Stock of LabCorp, if any, subject to the terms of the Zero Coupon Notes and the Indenture, dated as of October 24, 2006 between LabCorp and T... 
Printer Friendly Version